| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $5.9M | +83.0% |
| SG&A Expense | $6.4M | +29.2% |
| Operating Income | -$12.4M | -50.5% |
| Net Income | -$12.5M | -52.3% |
| EPS (Basic) | -$0.90 | +29.7% |
| EPS (Diluted) | -$0.90 | +29.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $6.2M | -11.2% |
| Current Assets | $6.9M | -10.2% |
| Total Assets | $7.6M | -1.4% |
| Current Liabilities | $1.5M | +74.8% |
| Total Liabilities | $1.5M | +74.2% |
| Stockholders' Equity | $6.2M | -10.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$9.8M | -40.5% |
| Investing Cash Flow | -$300K | — |
| Financing Cash Flow | $9.3M | +96.3% |